Jamshed Bomanji OBE is a full professor, clinical lead, and head of the Institute of Nuclear medicine department at the University College Hospital (UCLH) NHS foundation trust based in London, UK.[1]
Professor Bomanji obtained a graduate degree in 1980, and a PhD in 1987. His current interests are in the area of diagnostic and therapeutic of Neurology, Oncology, Cardiology, and Nephrology/Urology using Nuclear medicine.
Jamshed Bomanji also serves as the editor-in-chief at the Nuclear Medicine Communications.[2] His comments on cancer procedures using nuclear medicine techniques are documented by Hospitals[3] and private companies.[4][5][6]
Jamshed has authored 20 book Chapters.[1] Some of them are in the areas including, not limited to, Neuroendocrine Tumours,[7] Tissue Characterization,[8] Molecular radiotherapy in Children,[9] and Brain Disorder.[10] He has an edited book titled "A History of Radionuclide Studies in the UK: 50th Anniversary of the British Nuclear Medicine".[11] He is Editor Hybrid Imaging series, 14 books.
He has published more than 295 scientific Manuscripts, with over 6000 Citations.[12] His manuscript titled "Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga‐DOTATATE (DOTA‐D Phe1,Tyr3‐octreotate) and 18F‐FDG" published in 2008 has been cited more than 300 times alone. He published his first research paper in 1984 titled "123 I meta-iodo-benzyl guanidine: Synthesis and imaging the adrenal medulla and phaeochromocytoma" in the Journal of Nuclear Medicine in Research and Practice. Launched new suite of educational PET/CT webinars for the British Institute of Radiology 2019.
{{cite book}}: CS1 maint: multiple names: authors list (link)
{{cite book}}: CS1 maint: multiple names: authors list (link)
